You reviewed ....
for this content
out of 5
Event : Heart Failure 2019
Topic : Other
Benefits of full yogic breathing for patients with chronic heart failure
Heart Failure 2019
Analysis of the effectiveness of health education imparted by nursing in an heart failure unit
Comparative analysis of the European Heart Failure Self-Care Behavior Scale and the Self-care of Heart Failure Index in hospitalized patients with heart failure.
Utility of the implementation of a standardized evaluation program for therapeutic adherence in heart failure
A propensity-matched study of moderate to severe obesity and mortality in heart failure
The influence of socio-clinical variables on the level of self-care in heart failure patients
Effects of time perspective and executive function on self-care in patients with heart failure: a cross-sectional study
Real world usage and outcomes of all HFrEF patients treated with sacubitril/valsartan in Belgium
Sacubitril-valsartan and its effect on ventricular remodeling
Short and medium-term safety and tolerability of Sacubitril-Valsartan and Empaglifozin joint intake
Angiotensin receptor-neprilysin inhibition improves peak oxygen consumption in reduced heart failure patients
Sacubitril/Valsartan use in a real world experience: data from a large single-center population of heart failure patients with reduced ejection fraction
Use of sacubitril-valsartan in elderly patients. Subanalysis of the SAVE-RLife study
Allopurinol safety and efficacy in heart failure patients: a systematic review
Initial experience of a nursing consultation in the uptitration of neurohumoral treatment in patientes with heart failure and reduced ejection fraction
The impact of the use of sacubitril/valsartan on clinical and echocardiographic parameters in heart failure patients
The efficacy of "Get With the Guidelines Heart Failure," a retrospective analysis
Echocardiographic assessment of treating patients with chronic heart failure with mid-range ejection fraction by external counterpulsation
Early effects of Sacubitril/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction.
In-hospital management of disease modifying drugs in heart failure with reduced ejection fraction - an opportunity to improve?
Adherence to therapy in patients with chronic heart failure
Hemodynamic and clinical effects of ARNI therapy in patients with advanced heart failure undergoing repeated Levosimendan infusions
Quality of heart failure treatment treated by residential cardiologists -The HeartFailureBavaria Project
To evaluate the safety and tolerability of ARNI initiation in inpatient versus outpatient setting in an Asian population: a real world study
The optimize-heart failure care program in our heart institute in Vietnam
Inpatient versus outpatient introduction of angiotensin receptor neprilysin inhibitor in chronic heart failure patients
Management of patients with advanced heart failure and type 2 pulmonary hypertension.
Neuroendocrine inhibition in patients with heart failure and severe aortic stenosis undergoing TAVI
Levosemindan using in pediatric patients with end-stage heart failure: single center experience.
Availability and accessibility to heart failure treatment in latin america
Decongestion therapy: does it differ from discharge to usual life conditions and among heart failure patients?
The European Heart Failure self-care behaviour scale: psychometric testing of the Hebrew version
Small tolerated enalapril doses before ARNI administration predicts adverse events during ARNI up-titration
Prescription of sacubitril/valsartan in a real-world population
Use of sacubitril-valsartan in heart failure with reduced ejection fraction: real world experience
The dangers of non-heart failure hospitalisation for heart failure patients: frequent medication changes without follow up
Clinical, echocardiographic and cost improvement after the onset with sacubitril-valsartan in mexican patients with heart failure.
The efficacy of nicorandil for patients with ischemic chronic heart failure
Sequential nephron blockade with diuretics improves diastolic dysfunction in patients with resistant hypertension
Optimising heart failure treatment following cardiac resynchronisation therapy
Trimetazidine management: an extraordinary clinical response in patients with heart failure (TRIMEX-Study)
Careful volume assessment appears to be the critical factor in achieving clinical trial dose of sacubitril/valsartan in the community.
Cardiopulmonary exercise testing as a fundamental tool in the assessment of the functional class in treating sacubitril / valsartan. Results at 3 months
Safety profile of sacubitril-valsartan in heart failure with reduced ejection fraction with chronic kidney disease, a real life study
Early left ventricular reverse remodeling after sacubitril-valsartan treatment. Subanalysis of SAVE-RLife study
Impacts of mineralocorticoid receptor antagonists on mortality in heart failure patients with beta-blockers
Response rate to sacubitril-valsartan in the community. Is there a clear phenotype?
Treatment of patients with heart failure with reduced ejection fraction (HFrEF) in Germany: differences between cardiologists and primary care physicans
Effects of sacubitril/valsartan on cardiac performance and exercise capacity
Self-motivation, self-regulation and self-care in patients with heart failure: a sequential mixed-method study
Get your access to resources
Our mission: To reduce the burden of cardiovascular disease